Semuloparin sodium
Sponsors
Sanofi
Conditions
CancerThrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL)Venous Thromboembolism
Phase 2
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
CompletedNCT00331838
Start: 2006-05-31End: 2007-06-30Updated: 2013-01-15
Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line
TerminatedNCT01567904
Start: 2012-05-31End: 2012-07-31Updated: 2016-05-03
Phase 3
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
CompletedNCT00679588
Start: 2008-04-30End: 2010-08-31Updated: 2013-12-16
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
CompletedNCT00694382
Start: 2008-06-30End: 2010-11-30Updated: 2013-01-23
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
CompletedNCT00697099
Start: 2008-06-30End: 2009-06-30Updated: 2013-01-23
Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery
CompletedNCT00709904
Start: 2008-06-30End: 2010-01-31Updated: 2013-06-14
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility
TerminatedNCT00714597
Start: 2008-07-31End: 2009-03-31Updated: 2013-01-23
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
CompletedNCT00718224
Start: 2008-07-31End: 2009-05-31Updated: 2013-01-23
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery
CompletedNCT00721760
Start: 2008-07-31End: 2009-10-31Updated: 2013-01-23